Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 12,455,923.58, down 10.23% year-over-year[12] - Operating revenue for Q1 2024 reached CNY 70,024,905.48, representing a 5.04% increase from the same period last year[12] - Total operating revenue for Q1 2024 reached ¥70,024,905.48, an increase of 5.1% compared to ¥66,663,253.61 in Q1 2023[35] - Total operating costs for Q1 2024 were ¥56,990,296.85, up 9.3% from ¥52,296,461.49 in Q1 2023[35] - Net profit for Q1 2024 was ¥11,654,102.60, a decrease of 9.9% from ¥12,931,524.95 in Q1 2023[37] - Basic earnings per share for Q1 2024 were ¥0.31, down from ¥0.42 in Q1 2023[38] - The total profit for Q1 2024 was ¥13,910,390.75, down from ¥15,113,138.32 in Q1 2023, indicating a decline of 8.0%[37] - The company’s total comprehensive income for Q1 2024 was ¥11,654,102.60, compared to ¥12,931,524.95 in Q1 2023, reflecting a decrease of 9.9%[37] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, totaling CNY 4,540,309.86, an increase of 171.12% compared to the previous year[14] - Operating cash flow for Q1 2024 was 4,540,309.86 CNY, a significant improvement from -6,383,753.48 CNY in Q1 2023, indicating a turnaround in operational efficiency[42] - Total cash inflow from operating activities increased to 71,653,607.49 CNY in Q1 2024, up from 46,884,838.57 CNY in the same period last year, reflecting a growth of approximately 52.8%[42] - Cash outflow from operating activities rose to 67,113,297.63 CNY in Q1 2024, compared to 53,268,592.05 CNY in Q1 2023, marking an increase of about 25.9%[42] - Cash and cash equivalents decreased from 68,776,270.48 to 56,301,767.43, a decline of approximately 18.5%[29] - Cash and cash equivalents at the end of Q1 2024 stood at 44,857,074.24 CNY, down from 127,014,192.68 CNY at the end of Q1 2023, indicating a decrease of approximately 64.7%[44] - The parent company reported a cash and cash equivalents balance of 46,377,839.86 CNY at the end of Q1 2024, down from 122,417,624.85 CNY at the end of Q1 2023, representing a decrease of approximately 62.1%[46] Assets and Liabilities - Total assets as of March 31, 2024, were CNY 532,147,333.67, a decrease of 0.23% compared to the end of 2023[12] - The company's asset-liability ratio (consolidated) was 10.02%, a slight decrease from 10.46% at the end of 2023[12] - Total liabilities decreased from ¥66,215,014.88 to ¥53,312,852.20, a reduction of about 19.5%[31] - Current liabilities decreased from ¥62,854,855.02 to ¥50,232,681.45, a decrease of approximately 20.1%[30] - Non-current liabilities decreased from ¥3,360,159.86 to ¥3,080,170.75, a decline of about 8.3%[30] - Shareholders' equity increased from ¥467,180,378.87 to ¥478,834,481.47, an increase of approximately 2.8%[31] Shareholder Information - The total number of ordinary shareholders was 3,770 as of the report date[19] - The top ten shareholders hold a total of 22,011,826 shares, representing 54.81% of the company's total shares[20] - The largest shareholder, Dong Laishan, owns 15,741,786 shares, accounting for 39.20% of the total shares[20] - The company has no shareholders with pledged or judicially frozen shares[21] Research and Development - Research and development expenses increased by 36.98% to CNY 4,870,939.79, indicating a focus on innovation[13] - Research and development expenses increased to ¥4,870,939.79 in Q1 2024, compared to ¥3,555,986.54 in Q1 2023, reflecting a growth of 37%[35] Sales and Expenses - Accounts receivable rose by 65.16% to CNY 26,027,824.13, attributed to increased sales within credit terms[13] - The company reported a significant increase in sales expenses by 68.73% to CNY 570,707.64 due to the expansion of the sales team[13] - Accounts receivable increased significantly from 15,759,180.82 to 26,027,824.13, representing a growth of about 65.1%[29] - Inventory decreased from ¥45,327,819.01 to ¥40,070,509.10, a reduction of about 11.6%[32] Investment Activities - Investment activities resulted in a net cash outflow of -16,137,949.28 CNY in Q1 2024, an improvement from -43,250,393.84 CNY in Q1 2023, showing a reduction in investment losses[44] - The total cash inflow from investment activities was 10,358,891.04 CNY in Q1 2024, compared to 70,067.51 CNY in Q1 2023, reflecting a substantial increase[44] - The company received 10,000,000.00 CNY from investment recoveries in Q1 2024, with no such recoveries reported in Q1 2023[44] Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[24] - The company has fulfilled all previously disclosed commitments without any major changes during the reporting period[25] - The company has not engaged in any major asset acquisitions, sales, or external investments during the quarter[24]
峆一药业(430478) - 2024 Q1 - 季度财报